Karen Miotto, MD, DFASAM, DFAPA, CSAM President
Dr. Karen Miotto is the President of CSAM (2021 - 2023). She is a Professor in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA, where she focuses on physician and medical trainee health and wellness. Dr. Miotto is the Director of the UCLA Physician and Faculty Wellness Program and the Behavioral Wellness Center. Her extensive research career centers on improving treatments and pharmacotherapy for addictive disorders. Dr. Miotto's commitment to CSAM spans decades: she has chaired the Opioid Committee and Physician Wellbeing Committee, as well as led a Conference Planning Committee. In 2015, she was awarded the CSAM Vernelle Fox Award.
No relevant financial relationship to disclose. 

Sophia Achab, MD, MSc, PhD, MAS
Psychiatrist and psychotherapist specialized in addiction medicine and senior lecturer at Faculty of Medicine of Geneva University. Medical Director of the Swiss pioneering treatment Centre ReConnect specialized in addictive behaviors (Internet, Gambling, Gaming..) at University Hospitals of Geneva in Switzerland active since 2007. Developed a unique fit between clinical practice, research, teaching and public health mandates in this emergent medical field, advocating for a balance between opportunities and health risks of tech. Representative for Europe at Regional Council of ISAM, Co-chair of the executive committee of ISAM-NeXT, and Steering Committee of Global expert Network at ISAM. Board member of International Society for the Study of Addictive Behaviors (ISSBA).

Head of WHO Collaborating Centre for Training and Research in Mental Health, and responsible for collaborating activities on addictive disorders and behaviors. She has been part since 2013 of several technical advisory groups (TAGs) for international  (WHO) and Swiss policy making and public health entities in the field of Internet-related disorders. PhD in Life sciences with a research line on “Population and clinical perspectives of Behavioral addictions”. Published the last decade 155+ scientific works including 3 thesis and 13 book chapters.
No relevant financial relationship to disclose. 

Anthony Albanese, MD, FACP, DFASAM
Dr. Albanese is a gastroenterologist, hepatologist, and addiction medicine specialist. He is Chief of Medicine for the VA Northern California Healthcare System and Clinical Professor of Medicine and Psychiatry at the UC Davis School of Medicine. He was the 2012 Review Course Chairman, 2018 State of the Art Course Vice Chairman, and was CSAM President from 2019-2021. He is now on the CSAM Executive Council as Immediate Past President, and  serves on  the ASAM Board of Directors as Chairman of the Chapters Council. He has been practicing Addiction Medicine and Hepatology for the past 30 years in a variety of settings including methadone clinic, private practice, full service treatment facilities, academic centers and impaired professional programs.

Sara Bagley, MD, MSc
Sarah Bagley is an Assistant Professor of Medicine and Pediatrics at Boston University School of Medicine, and an Attending Physician in General Internal Medicine and Pediatrics at Boston Medical Center. Sarah attended Georgetown University School of Medicine and then completed a Combined Internal Medicine and Pediatrics at Brown University and an Addiction Medicine Fellowship at Boston University School of Medicine. She is the founder and Medical Director of CATALYST at Boston Medical Center providing integrated substance use care and primary care for patients less than 25 years old.  Her research focus is on the engagement of young adults who use drugs and their families in care to minimize risk for overdose and the complications of drug use. She has funding from the National Institute on Drug Abuse and the Centers for Disease Control and Prevention to conduct research about engaging people in care after nonfatal drug overdose.
No relevant financial relationship to disclose. 

Roshan Bhad, MD
Professor of Psychiatry at the National Drug Dependence Treatment Centre (NDDTC), All India Institute of Medical Sciences (AIIMS), New Delhi. He is also on the board of directors (Ex-Officio) at the International Society of Addiction Medicine (ISAM). He completed his post-graduation in psychiatry (MD), in the year 2012 from AIIMS, Delhi, India. and developed an interest in Addiction Medicine 10 years back during his clinical work in a community addiction treatment program and was especially inspired by patients who had dramatic improvement after taking opioid agonist treatment. He received the NIDA-ISAM fellowship award in 2015 and qualified for International Certification in Addiction Medicine in the same year. He was recognized as a fellow of ISAM in the year 2019. His areas of clinical/research interests are addictive behaviors among adolescents and youth, community addiction psychiatry, consultation-liaison addiction psychiatry, drug policy & public health. Belonging to a developing country, he aspires to improve the outreach of addiction medicine training and research globally and particularly in low- and middle-income countries. He is presently the Chairperson of ISAM NExT (New Professionals Exploration Training & Education), a committee of 30 energetic and enthusiastic young addiction medicine professionals from 20 countries.
No relevant financial relationship to disclose. 

Sara Buckelew, MD
Sara M Buckelew, MD, MPH is Professor of Pediatrics af University of California, San Francisco. She completed medical school at the University of Pennsylvania and residency at Childrens Hospital Los Angeles. She is an Adolescent Medicine specialist, completing an Adolescent and Young Adult Medicine at UCSF. She is the Medical Director of the UCSF Adolescent and Young Adult Eating Disorder Program and Associate Chief of the Division of Adolescent and Young Adult Medicine.
No relevant financial relationship to disclose. 

Phillip Coffin, MD, MIA
Phillip Coffin MD, MIA is a board-certified and practicing internist, infectious disease specialist, and addiction medicine specialist. He directs the Center on Substance Use and Health at the San Francisco Department of Public Health, including clinical trials assessing medications for multiple substance use disorders and interventions for opioid safety, overdose prevention, and prevention or management of other sequelae of substance use. He also conducts epidemiologic and other observational studies.
No relevant financial relationship to disclose. 

Smita Das, MD, PhD, MPH
Dr. Das is Board Certified in Psychiatry, Addiction Psychiatry and Addiction Medicine and has over 20 years of research experience in health care quality and addiction. A native of the San Francisco Bay Area (San Jose), she studied Chemistry and Statistics at Stanford, completed her Masters in Public Health at Dartmouth College, and then completed her MD/PhD in Community Health at the University of Illinois at Urbana Champaign. Regionally, she has been a leader in the Northern California Psychiatric Society since 2012 and is a Past President of the American Psychiatric Association (APA) District Branch. Nationally, she serves on the Council on Addictions at the American Psychiatric Association, has presented to the US Congress and is an invited speaker at national conferences. Prior to her position as Medical Director of Psychiatry at Lyra Health, she was Director of Addiction Treatment Services at the Palo Alto VA System. In addition to her work at Lyra, Dr. Das practices in addictions at Stanford School of Medicine where she is a Clinical Associate Professor.
No relevant financial relationship to disclose. 

Amy de la Garza, MD
I am a family practice physician who has dedicated a large part of my training and professional practice to the care of patients with substance use disorder (SUD). In 2017 I opened the first community based co-located behavioral health and SUD outpatient clinic in SLC.  Last year I completed a fellowship in Addiction Medicine at the University of Utah and will sit for my ABPM Addiction Medicine Board Certification this fall. In 2021 I also completed a two-year training to become an Institute for Functional Medicine Certified Practitioner (IFMCP). I am certified in auricular acudetox by the National Acupuncture Detoxification Association and have completed my initial training in Mindfulness Oriented Recovery Enhancement with Dr. Eric Garland.

Integrative care for SUD includes lifestyle behavior modification and complementary therapies rooted in the biopsychosocial model. Patients with behavioral health diagnoses, including SUD, should receive behavioral health focused primary care, lifestyle education and support including nutrition, exercise, sleep, stress management and the importance of connectivity and complementary therapies including acupuncture, neutraceuticals and botanicals, and mindfulness-based interventions.

In late 2021 I joined Novamind as the Medical Director of the downtown SLC location and the Director of Substance Use Disorder Programming.  Novamind is committed to providing innovative therapeutic modalities to patients with behavioral health conditions as well as conducting research in the application of psychedelics to these diagnoses. My role includes the development of Integrative Behavioral Healthcare and its application to the treatment of patients with this most difficult diagnosis.
No relevant financial relationship to disclose. 

Jeffrey Devido, MD
After completing a Masters in Theological Studies at Harvard Divinity School Dr DeVido entered medical school at Columbia University's College of Physicians and Surgeons.  He went on to complete adult psychiatry and addiction psychiatry training at Massachusetts General and McLean Hospitals before earning board certification in adult and addiction psychiatry, and then addiction medicine (ABPM).  Dr. DeVido came to San Francisco in 2013 as a Clinical Assistant Professor at UCSF, in the division of consultation liaison psychiatry.  In 2016 he became Chief, Addiction Services, at Marin County Health and Human Services, where he has helped develop and oversee addiction programing for Marin Medi-Cal beneficiaries through Marin's Drug Medi-Cal Organized Delivery System (DMC-ODS) and serves as medical director for Marin County's DMC-ODS co-occurring direct service program.  In addition, in 2018 Dr DeVido became Behavioral Health Clinical Director at Partnership HealthPlan of CA, a managed Medi-Cal Health Plan that services beneficiaries in 14 CA counties between San Francisco and the Oregon border.  In this role, Dr DeVido works to develop and oversee behavioral health program integration throughout Partnership's network.  His particular interests are in integration of behavioral healthcare into primary medical settings; quality improvement in behavioral healthcare programing; and novel approaches to community/healthcare system collaborations to decrease overdoses and improve motivation for treatment engagement.
Disclosure: Philip Morris/Altria; Merck - Stock

Lisa Fortuna, MD, MPH
Lisa Fortuna, MD, MPH, M.Div isProfessor of Clinical Psychiatry and Behavioral Sciences at UCSF and the Chief of Psychiatry and Vice-Chair at Zuckerberg San Francisco General Hospital. She is Board Certified in Psychiatry, Child and Adolescent Psychiatry and Addiction Medicine. She is also an ordained minister in the Episcopal Church USA. Her areas of expertise include child  and adolescent psychiatry, Posttraumatic Stress Disorder, substance use disorders in adolescents, spirituality and religion in mental health, and intervention research with immigrant, Latino and other communities of color. She has been an investigator on several NIH studies and published several articles in these areas of her expertise.  Her book, Mindfulness-Based CBT for Adolescent PTSD and Addictions, was published by New Harbinger Press in October 2015.
No relevant financial relationship to disclose. 

Joy Hao, MD, PhD
Dr. Joy Hao graduated from the MD-PhD program at New York University School of Medicine in 2007, and subsequently completed Internal Medicine residency training in the Social Medicine track at Montefiore Medical Center and Albert Einstein College of Medicine in Bronx, New York. After working at a Federally Qualified Health Center in Chinatown serving a mostly immigrant population, Dr. Hao transitioned from primary care to addiction medicine and began providing methadone maintenance therapy at an Opiate Treatment Program in Manhattan. In 2014, she relocated to California and accepted an appointment as an Assistant Clinical Professor at UCLA, where she worked closely with the UCLA Comprehensive Pain Center in the management of opioid-dependent patients with chronic pain using buprenorphine. Since 2019, Dr. Hao has also taken on the roles of the Medical Director of the West Los Angeles VA Substance Use Disorder Clinic and Opiate Treatment Program, as well as Site Director of the Teaching Clinic, where she supervises a large number of trainees across multiple disciplines, including Addiction Psychiatry fellows, Psychiatry residents, and Addiction Medicine fellows from UCLA and the VA. She remains actively involved as a core faculty member of the Addiction Medicine Fellowship at the UCLA Department of Family Medicine. Dr. Hao has been a regular attendee of the California Society of Addiction Medicine annual conference since 2014 and is honored to be part of the Planning Committee. She enjoys playing piano duets with her 8-year-old daughter in her spare time.
No relevant financial relationship to disclose. 

Christy Huff, MD
Christy Huff, MD, is a cardiologist and director of Benzodiazepine Information Coalition, a nonprofit that educates about the adverse effects of prescribed benzodiazepines. Dr. Huff attended medical school at the University of Texas Southwestern where she graduated Alpha Omega Alpha. She completed an internal medicine residency at Washington University in St. Louis and a cardiology fellowship at U.T. Southwestern, with a focus in advanced cardiovascular imaging and noninvasive cardiology. Dr. Huff is a Fellow of the American College of Cardiology, and was a private practice cardiologist in Fort Worth,Texas until 2011, when she became a stay-at-home mom after the birth of her daughter.

Dr. Huff speaks and writes frequently about her lived experience with benzodiazepines. In 2015, she experienced adverse effects after three weeks of prescribed Xanax for insomnia. Over a three-year period, she slowly tapered off benzodiazepines utilizing Valium, and suffered protracted and disabling symptoms. Her personal experience led her to realize the serious risks of these medications and the potential severity of benzodiazepine withdrawal syndrome, neither of which were emphasized during her medical training. Dr. Huff specifically advocates for better education of physicians regarding the adverse effects of benzodiazepines and how to safely taper patients off these medications. Her research interests include patient-centered benzodiazepine deprescribing and benzodiazepine-induced neurological dysfunction (BIND).  In addition to her work at BIC, Dr. Huff is a member of the Colorado Consortium’s Benzodiazepine Action Work Group.
No relevant financial relationship to disclose. 

Tipu Khan, MD, FAAFP, FASAM
Fellowship Director - Primary Care Addiction Medicine Fellowship. Dr. Khan earned his BA in Philosophy and his BS in Neurobiology, Physiology and Behavior from UC Davis. He went on to earn his MD from the University of Washington with a certificate in The Underserved Pathway. Dr. Khan completed his residency training at Harbor/UCLA and an Obstetrics fellowship at CHMC/USC. He worked in South Central Los Angeles for two years and then joined faculty at Ventura in 2014. His clinical practice includes emergency medicine, high risk obstetrics including addiction in pregnancy, inpatient medicine, addiction medicine, street and international medicine, and quality improvement and scholarly activity. He is a board certified Addiction Specialist. He enjoys endurance running, mountain biking, and anything outdoors with the kids!
Disclosure: Abbvie - Speaker's Bureau; Alkermes - Advisory Board Member

George Koob, PhD
George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).  As NIAAA Director, Dr. Koob oversees a wide range of alcohol-related research, including genetics, neuroscience, epidemiology, prevention, and treatment. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence.  Dr. Koob has published over 700 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field. He has mentored 11 Ph. D students and over 80 post-doctoral fellows. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972.  He was a post-doctorl fellow in the Department of Experimental Psychology and the MRC Neuropharmacology Unit at the University of Cambridge.  He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders.  He has also served as a researcher in the Department of Neurophysiology at the Walter Reed Army Institute of Research and the Arthur Vining Davis Center for Behavioral Neurobiology at the Salk Institute for Biological Studies.  Dr. Koob is the recipient of many presitgious honors and awards recognizing his contributions to research, mentorship, and international scientific collaboration.
No relevant financial relationship to disclose. 

Erica LaFata Schulte, PhD
No relevant financial relationship to disclose. 

David Lawrence, MD, FASAM
George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).  As NIAAA Director, Dr. Koob oversees a wide range of alcohol-related research, including genetics, neuroscience, epidemiology, prevention, and treatment. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence.  Dr. Koob has published over 700 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field. He has mentored 11 Ph. D students and over 80 post-doctoral fellows. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972.  He was a post-doctorl fellow in the Department of Experimental Psychology and the MRC Neuropharmacology Unit at the University of Cambridge.  He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders.  He has also served as a researcher in the Department of Neurophysiology at the Walter Reed Army Institute of Research and the Arthur Vining Davis Center for Behavioral Neurobiology at the Salk Institute for Biological Studies.  Dr. Koob is the recipient of many presitgious honors and awards recognizing his contributions to research, mentorship, and international scientific collaboration.
No relevant financial relationship to disclose. 

Larissa Lindsey, PhD
Dr. Larissa Lindsey (formerly Larissa Maley) is a licensed psychologist and the acting Clinical Director for the University of New Mexico Hospitals behavioral health programs. In that role, she is responsible for the development, implementation, and on-going quality assessment of evidence based, trauma informed clinical programming for inpatient and outpatient clinical services. Furthermore, she is a certified provider of numerous evidence based psychotherapies for both PTSD and substance use disorders, and she has worked as a research coordinator and research clinician on several SAMHSA grant funded research projects specific to individuals with substance use disorders, and/or comorbid mental health issues.
No relevant financial relationship to disclose. 

Pam Ling, MD, MPH
Dr. Pamela Ling is Professor of Medicine and Director of the Center for Tobacco Control Research and Education at the University of California San Francisco.  Her research focuses on tobacco, media, social marketing, and young adults.  The work includes analyses of thousands of previously secret tobacco industry documents detailing industry marketing strategies. Dr. Ling has special interest in the marketing of novel tobacco products including e-cigarettes, the global proliferation of U.S. tobacco marketing strategies, and using market research strategies to inform innovative clinical and public health interventions.  She has contributed to three Surgeon General’s Reports on Tobacco and has been member of the American Society for Clinical Investigation since 2016.  Dr. Ling has an active clinical practice in General Internal Medicine.
No relevant financial relationship to disclose. 

Jiang Long, MD, PhD
Jiang LONG, M.D./ Ph.D. in Psychiatry and Mental Health, is currently working as a psychiatrist researcher at Shanghai Mental Health Center, a WHO Collaborating Centre for Research and Training in Mental Health (Shanghai, China). He has been systematically trained to be an addiction specialist in China and Belgium since 2005 and has led a series of programs in substance use and addictive behaviors at the WHO Department of Mental Health and Substance Use as well as the National Health Commission of China (Beijing, China). He is an expert member of the Chinese Association of Drug Abuse Prevention and Treatment and the WHO Expert Working Group for the Development of International Screening and Diagnostic Instruments for Gaming Disorder and Gambling Disorder.
No relevant financial relationship to disclose. 

Julio Meza, MD
Dr. Julio Meza is an Addiction and Family Medicine Physician at the David Geffen School of Medicine at UCLA and a Psychiatry in Primary Care Certified Physician at UC Irvine. Dr. Meza was born and raised in El Salvador. He graduated Cum Laude from Universidad Evangelica de El Salvador. After graduating from medical school, he was accepted into a surgical residency and completed an internship at the Hospital Militar Central in El Salvador. He left El Salvador to pursue his dream of becoming a U.S. licensed family physician. While in Los Angeles, Dr. Meza worked as a medical assistant instructor and program director, training students to work in the areas of San Fernando, North Hollywood and Los Angeles then joined UCLA and completed his residency in Family Medicine and also Fellowship in Addiction Medicine. Dr. Meza enjoys working with patients from all backgrounds and provides non judgmental compassionate care.
No relevant financial relationship to disclose. 

Elizabeth Miranda Saenz, MD, MPHDC, MMCH

Marc Potenza, MD, PhD
Dr. Potenza is a board-certified psychiatrist with sub-specialty training in addiction psychiatry.  He completed undergraduate, graduate, medical, internship, psychiatric residency and addiction psychiatry fellowship training at Yale.  Currently, he is a Professor of Psychiatry, Child Study and Neuroscience at the Yale University School of Medicine where he is the Director of the Division on Addictions Research, the Problem Gambling Clinic, the Center of Excellence in Gambling Research, the Women and Addictive Disorders Core of Women's Health Research at Yale and the Yale Research Program on Impulsivity and Impulse Control Disorders.  He is also a Senior Research Scientist at the Connecticut Council on Problem Gambling. He is on the editorial boards of fifteen journals (including editor-in-chief of Current Addiction Reports) and has received multiple national and international awards for excellence in research and clinical care.  He has participated in two DSM-5 research work groups and six annual WHO meetings relating to Internet use and addictive behaviors in the ICD-11, addressing topics relating to gambling, gaming, impulse control, and addiction.
Disclosure: Idorsia; AXA; Baria-Tek - Consulting Fee; Opiant - Advisory Board; Novartis (with Yale) - Patent Application

Lara Ray, PhD
Dr. Lara Ray received her PhD in Clinical Psychology from the University of Colorado at Boulder. Dr. Ray completed a predoctoral clinical internship at Brown University Medical School where she stayed for a postdoctoral fellowship at the Brown University Center for Alcohol and Addiction Studies. After her postdoctoral fellowship, Dr. Ray joined the faculty at the UCLA Clinical Psychology Program where she is now a Full Professor. Dr. Ray also has academic appointments in the UCLA Department of Psychiatry and Human Behavior and the UCLA Brain Research Institute. Dr. Ray has an active program of research on clinical neuroscience of addiction. Her laboratory combines experimental psychopharmacology with behavioral genetic and neuroimaging methods to ascertain the mechanisms underlying addictive disorders in humans and applying these insights to treatment development. Dr. Ray has over 250 peer-reviewed publications and book chapters. Her program of research is funded by the National Institute on Alcohol and Abuse and Alcoholism (NIAAA) as well as the National Institute on Drug Abuse (NIDA). Dr. Ray has received research excellence awards from the American Psychological Association (APA), the Research Society on Alcoholism (RSA), and the American College on Neuropsychopharmacology (ACNP).
Disclosure: Alermes - Consultant

Joanna Shepherd, MD
JoAnna is board certified and trained in internal medicine and pediatrics. she is also board certified in addiction medicine and transitioned to workimg full time in adolecent and adult addiction medicine at Kaiser in the summer of 2021.
No relevant financial relationship to disclose. 

Stacie Solt, MD
No relevant financial relationship to disclose. 

Matthew Torrington, MD, ABAM, ABPM, AAFP, DFASAM
Dr Torrington is a board certified in Family Medicine and Addiction Medicine.  He is a distinguished fellow of the American Society of Addiction Medicine, the chair of the Committee on Treatment of Opioid Dependence of the California Society of Addiction Medicine, and is a certified Medical Review Officer. Dr Torrington’s clinical focus is the treatment of stimulant use disorders, alcohol use disorders, opiate use disorders, and pain. As a participant in the development and implementation of significant research studies, he has served as Principal Investigator, co-investigator, and study physician for numerous clinical trials.  For over twenty years,  Dr Torrington has been involved in the clinical use, clinical research, and education of physicians regarding various formulations of buprenorphine. In 2007, Dr. Torrington started a treatment venue in association with Common Ground Westside in Santa Monica, CA providing no-cost, low-barrier care to people with addiction issues. In 2016 the venue was subsumed by the Venice Family Clinic. Dr. Torrington continued to support the effort, providing care pro bono to those in need, and delivering clinical instruction to numerous providers until the clinic became fully self sufficient in 2021. Dr. Torrington has contributed to many inpatient, outpatient and residential treatment centers providing a wide range of treatment to those in need.  Dr. Torrington’s private practice is focused on helping those suffering with addiction and pain develop and implement comprehensive individualized multimodal treatment plans that address the biologic, psychological, social, spiritual and nutritional factors in their lives.
No relevant financial relationship to disclose. 

Ori Tzvieli, MD
Masters in 1998 from UC Berkeley School of Public Health and MD in 2000 from UCSF. In 2003 completed Contra Costa Family Medicine Residency. Had a long standing primary care practice with a career-long interest in addiction and stigmatized populations. Helped create and lead Choosing Change, a county-FQHC sponsored MAT program serving >900 patients a year.  Serves as county director of Public Health and Health Officer and is one of the leaders in Cal-Omri, Contra Costa's collaboration between EMS, Public Health, and the Clinical Delivery System that focuses on expanding MAT through EMS collaboration.
No relevant financial relationship to disclose.